ClinicalTrials.gg
CompletedNCT06440980Updated Jul 17, 2026Results posted

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

A Phase 1 interventional study of Orforglipron in Healthy, Obese and Overweight, sponsored by Eli Lilly and Company. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
533
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
9th of 22
533 · median 324
Started
2024
with 5 others
Phase 1
6 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 9th largest by enrollment, is one of 6 that started in 2024, is one of 6 in phase 1, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated.

The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

03

Conditions studied

  • Healthy
  • Obese
  • Overweight
  • Obesity

Keywords

  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical history and physical examination.
  • Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and (BMI) in range of 27 to 40 kilogram per meter square (kg/m²).
  • Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  • Have venous access sufficient to allow for blood sampling.

Exclusion criteria

Exclusion Criteria:

  • Have (HbA1c) level of 6.5 percent (%) or greater.
  • Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions.
  • Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years.
  • Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.
  • Have known gastric emptying abnormality.
  • Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)
  • Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer.
  • Have an abnormal 12-lead (ECG) at screening.
  • Have history of pancreatitis.
  • Judged by the study investigator to be at serious suicidal risk and have answered "Yes" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS]).
  • Have difficulty swallowing capsules or tablets.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
533 participants (actual)

Study arms

  • Experimental
    Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)

    Participants received LY3502970 orally once daily (QD) across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule) * Period 2: Dose Level 2 (Tablet) * Period 3: Dose Level 1 (Tablet) * Period 4: Dose Level 3 (Tablet) * Period 5: 3 mg (Capsule) * Period 6: Dose Level 5 (Tablet) * Period 7: Dose Level 4 (Tablet) * Period 8: Dose Level 6 (Tablet) * Period 9: 6 mg (Capsule) * Period 10: Dose Level 8 (Tablet) * Period 11: Dose Level 7 (Tablet) * Period 12: Dose Level 9 (Tablet)

    Drug: Orforglipron

  • Experimental
    Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 2 (Tablet) * Period 2: 1 mg (Capsule) * Period 3: Dose Level 3 (Tablet) * Period 4: Dose Level 1 (Tablet) * Period 5: Dose Level 5 (Tablet) * Period 6: 3 mg (Capsule) * Period 7: Dose Level 6 (Tablet) * Period 8: Dose Level 4 (Tablet) * Period 9: Dose Level 8 (Tablet) * Period 10: 6 mg (Capsule) * Period 11: Dose Level 9 (Tablet) * Period 12: Dose Level 7 (Tablet)

    Drug: Orforglipron

  • Experimental
    Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 1 (Tablet) * Period 2: Dose Level 3 (Tablet) * Period 3: 1 mg (Capsule) * Period 4: Dose Level 2 (Tablet) * Period 5: Dose Level 4 (Tablet) * Period 6: Dose Level 6 (Tablet) * Period 7: 3 mg (Capsule) * Period 8: Dose Level 5 (Tablet) * Period 9: Dose Level 7 (Tablet) * Period 10: Dose Level 9 (Tablet) * Period 11: 6 mg (Capsule) * Period 12: Dose Level 8 (Tablet)

    Drug: Orforglipron

  • Experimental
    Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 3 (Tablet) * Period 2: Dose Level 1 (Tablet) * Period 3: Dose Level 2 (Tablet) * Period 4: 1 mg (Capsule) * Period 5: Dose Level 6 (Tablet) * Period 6: Dose Level 4 (Tablet) * Period 7: Dose Level 5 (Tablet) * Period 8: 3 mg (Capsule) * Period 9: Dose Level 9 (Tablet) * Period 10: Dose Level 7 (Tablet) * Period 11: Dose Level 8 (Tablet) * Period 12: 6 mg (Capsule)

    Drug: Orforglipron

  • Experimental
    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule) * Period 8: Dose Level 11 (Tablet) * Period 9: Dose Level 10 (Tablet) * Period 10: Dose Level 12 (Tablet) * Period 11: 24 mg (Capsule) * Period 12: Dose Level 14 (Tablet) * Period 13: Dose Level 13 (Tablet) * Period 14: Dose Level 16 (Tablet) * Period 15: 36 mg (Capsule) * Period 16: Dose Level 17 (Tablet) * Period 17: Dose Level 15 (Tablet) * Period 18: Dose Level 18 (Tablet)

    Drug: Orforglipron

  • Experimental
    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 11 (Tablet) * Period 8: 12 mg (Capsule) * Period 9: Dose Level 12 (Tablet) * Period 10: Dose Level 10 (Tablet) * Period 11: Dose Level 14 (Tablet) * Period 12: 24 mg (Capsule) * Period 13: Dose Level 16 (Tablet) * Period 14: Dose Level 13 (Tablet) * Period 15: Dose Level 17 (Tablet) * Period 16: 36 mg (Capsule) * Period 17: Dose Level 18 (Tablet) * Period 18: Dose Level 15 (Tablet)

    Drug: Orforglipron

  • Experimental
    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 10 (Tablet) * Period 8: Dose Level 12 (Tablet) * Period 9: 12 mg (Capsule) * Period 10: Dose Level 11 (Tablet) * Period 11: Dose Level 13 (Tablet) * Period 12: Dose Level 16 (Tablet) * Period 13: 24 mg (Capsule) * Period 14: Dose Level 14 (Tablet) * Period 15: Dose Level 15 (Tablet) * Period 16: Dose Level 18 (Tablet) * Period 17: 36 mg (Capsule) * Period 18: Dose Level 17 (Tablet)

    Drug: Orforglipron

  • Experimental
    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 12 (Tablet) * Period 8: Dose Level 10 (Tablet) * Period 9: Dose Level 11 (Tablet) * Period 10: 12 mg (Capsule) * Period 11: Dose Level 16 (Tablet) * Period 12: Dose Level 13 (Tablet) * Period 13: Dose Level 14 (Tablet) * Period 14: 24 mg (Capsule) * Period 15: Dose Level 18 (Tablet) * Period 16: Dose Level 15 (Tablet) * Period 17: Dose Level 17 (Tablet) * Period 18: 36 mg (Capsule)

    Drug: Orforglipron

  • Experimental
    Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 1 mg (Capsule- Second Treatment) * Period 3: 0.8 mg (Tablet) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 3 mg (Capsule- Second Treatment) * Period 6: 2.5 mg (Tablet) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 6 mg (Capsule- Second Treatment) * Period 9: 5.5 mg (Tablet)

    Drug: Orforglipron

  • Experimental
    Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 0.8 mg (Tablet) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 2.5 mg (Tablet) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 5.5 mg (Tablet) * Period 9: 6 mg (Capsule- Second Treatment)

    Drug: Orforglipron

  • Experimental
    Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 0.8 mg (Tablet) * Period 2: 1 mg (Capsule- First Treatment) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 2.5 mg (Tablet) * Period 5: 3 mg (Capsule- First Treatment) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 5.5 mg (Tablet) * Period 8: 6 mg (Capsule- First Treatment) * Period 9: 6 mg (Capsule- Second Treatment)

    Drug: Orforglipron

  • Experimental
    Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 12 mg (Capsule- Second Treatment) * Period 9: 9 mg (Tablet) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 24 mg (Capsule- Second Treatment) * Period 12: 14.5 mg (Tablet) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 36 mg (Capsule- Second Treatment) * Period 15: 17.2 mg (Tablet)

    Drug: Orforglipron

  • Experimental
    Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 9 mg (Tablet) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 14.5 mg (Tablet) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 17.2 mg (Tablet) * Period 15: 36 mg (Capsule- Second Treatment)

    Drug: Orforglipron

  • Experimental
    Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 9 mg (Tablet) * Period 8: 12 mg (Capsule- First Treatment) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 14.5 mg (Tablet) * Period 11: 24 mg (Capsule- First Treatment) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 17.2 mg (Tablet) * Period 14: 36 mg (Capsule- First Treatment) * Period 15: 36 mg (Capsule- Second Treatment)

    Drug: Orforglipron

Interventions

06

What researchers measure

Primary outcomes

  1. Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7

    PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC\[0-tau\] on Day 7.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)

  2. Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7

    PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)

07

Results

Posted Jul 17, 2026

Participant flow

This study enrolled 533 participants across 4 mutually exclusive cohorts in 2 parts: Part A (pilot relative bioavailability; Cohorts 1A and 2A) and Part B (bioequivalence; Cohorts 1B and 2B). As per sponsor decision, for Part A tablet (Cohorts 1A and 2A), dose levels are presented as Dose Level 1 through Dose Level 18, where Dose Level 1 represents the lowest dose and Dose Level 18 represents the highest dose.

Cohort 1A
Participant flow — Cohort 1A
MilestonePart A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)
Started131313130000000000
Period 1131313130000000000
Period 2131313130000000000
Period 3131313130000000000
Period 4131313130000000000
Period 5131312130000000000
Period 6131312130000000000
Period 7131310120000000000
Period 8131310110000000000
Period 9131310110000000000
Period 10131210110000000000
Period 11131210110000000000
Period 12131210110000000000
Completed131210100000000000
Not completed01330000000000
Withdrew: Adverse event00320000000000
Withdrew: Physician decision01000000000000
Withdrew: Withdrawal by subject00010000000000
Cohort 2A
Participant flow — Cohort 2A
MilestonePart A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)
Started000015121312000000
Home-dosing (period 1-6)000015121312000000
Period 7000013121312000000
Period 8000013121312000000
Period 9000013121312000000
Period 10000013121312000000
Period 11000013121312000000
Period 12000013121312000000
Period 13000013121312000000
Period 14000013111212000000
Period 15000011101212000000
Period 16000011101212000000
Period 17000011101212000000
Period 18000011101212000000
Completed000011101212000000
Not completed00004210000000
Withdrew: Adverse event00000100000000
Withdrew: Physician decision00000110000000
Withdrew: Withdrawal by subject00004000000000
Cohort 1B
Participant flow — Cohort 1B
MilestonePart A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)
Started00000000727272000
Period 100000000727272000
Period 200000000717071000
Period 300000000716971000
Period 400000000716971000
Period 500000000716870000
Period 600000000716769000
Period 700000000706768000
Period 800000000696666000
Period 900000000696566000
Completed00000000696466000
Not completed00000000386000
Withdrew: Adverse event00000000022000
Withdrew: Withdrawal by subject00000000212000
Withdrew: Physician decision00000000152000
Cohort 2B
Participant flow — Cohort 2B
MilestonePart A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)
Started00000000000876363
Period 1-600000000000876363
Period 700000000000636263
Period 800000000000626161
Period 900000000000626159
Period 1000000000000616159
Period 1100000000000606159
Period 1200000000000606158
Period 1300000000000596058
Period 1400000000000586057
Period 1500000000000586057
Completed00000000000586056
Not completed000000000002937
Withdrew: Withdrawal by subject00000000000914
Withdrew: Physician decision00000000000611
Withdrew: Adverse event00000000000812
Withdrew: Non-compliance with study drug00000000000100
Withdrew: Screen failure00000000000200
Withdrew: Protocol deviation00000000000300

Outcome measures

PrimaryPart B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7

PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC\[0-tau\] on Day 7.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)
Reported as:
Geometric mean · Nanogram* hours/milliliter (ng*h/ml)
Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7
Nanogram* hours/milliliter (ng*h/ml)Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment)Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment)Cohort 1B: 0.8 mg LY3502970 Tablet QDCohort 1B: 3 mg LY3502970 Capsule QD (First Treatment)Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment)Cohort 1B: 2.5 mg LY3502970 Tablet QDCohort 1B: 6 mg LY3502970 Capsule QD (First Treatment)Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment)Cohort 1B: 5.5 mg LY3502970 Tablet QDCohort 2B: 12 mg LY3502970 Capsule QD (First Treatment)Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment)Cohort 2B: 9 mg LY3502970 Tablet QDCohort 2B: 24 mg LY3502970 Capsule QD (First Treatment)Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment)Cohort 2B: 14.5 mg LY3502970 Tablet QDCohort 2B: 36 mg LY3502970 Capsule QD (First Treatment)Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment)Cohort 2B: 17.2 mg LY3502970 Tablet QD
Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 780.2 ± 37.882.1 ± 39.778.9 ± 36.6240 ± 38.8252 ± 39.1247 ± 37.3517 ± 47.4541 ± 60.4524 ± 45.4829 ± 46.4841 ± 46.3790 ± 40.31210 ± 50.01260 ± 57.51200 ± 64.21500 ± 71.51500 ± 71.91520 ± 60.4
PrimaryPart B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7

PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)
Reported as:
Geometric mean · Nanogram per milliliter (ng/ml)
Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7
Nanogram per milliliter (ng/ml)Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment)Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment)Cohort 1B: 0.8 mg LY3502970 Tablet QDCohort 1B: 3 mg LY3502970 Capsule QD (First Treatment)Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment)Cohort 1B: 2.5 mg LY3502970 Tablet QDCohort 1B: 6 mg LY3502970 Capsule QD (First Treatment)Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment)Cohort 1B: 5.5 mg LY3502970 Tablet QDCohort 2B: 12 mg LY3502970 Capsule QD (First Treatment)Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment)Cohort 2B: 9 mg LY3502970 Tablet QDCohort 2B: 24 mg LY3502970 Capsule QD (First Treatment)Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment)Cohort 2B: 14.5 mg LY3502970 Tablet QDCohort 2B: 36 mg LY3502970 Capsule QD (First Treatment)Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment)Cohort 2B: 17.2 mg LY3502970 Tablet QD
Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 75.39 ± 37.95.60 ± 39.55.38 ± 35.916.2 ± 41.216.8 ± 38.816.8 ± 37.435.1 ± 50.036.8 ± 63.634.9 ± 63.955.0 ± 55.055.6 ± 51.353.5 ± 41.780.0 ± 52.182.6 ± 60.682.2 ± 67.796.9 ± 74.496.2 ± 75.8105 ± 65.2

Adverse events

Collected over Cohort 1A: Baseline Up to end of follow up (Up to 13 weeks); Cohort 2A: Baseline Up to end of follow up (Up to 19 weeks); Cohort 1B: Baseline Up to end of follow up (Up to 10 weeks); Cohort 2B: Baseline Up to end of follow up (Up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1A: 1 mg LY3502970 Capsule QD0/52 (0%)0/52 (0%)6/52 (11.5%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 1)0/52 (0%)0/52 (0%)8/52 (15.4%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 2)0/52 (0%)0/52 (0%)7/52 (13.5%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 3)0/52 (0%)0/52 (0%)9/52 (17.3%)
Cohort 1A: 3 mg LY3502970 Capsule QD0/47 (0%)0/47 (0%)6/47 (12.8%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 4)0/51 (0%)0/51 (0%)9/51 (17.6%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 5)0/48 (0%)0/48 (0%)10/48 (20.8%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 6)0/51 (0%)0/51 (0%)13/51 (25.5%)
Cohort 1A: 6 mg LY3502970 Capsule QD0/46 (0%)0/46 (0%)7/46 (15.2%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 7)0/46 (0%)0/46 (0%)6/46 (13%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 8)0/47 (0%)0/47 (0%)7/47 (14.9%)
Cohort 1A: LY3502970 Tablet QD (Dose Level 9)0/46 (0%)0/46 (0%)10/46 (21.7%)
Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)0/52 (0%)0/52 (0%)11/52 (21.2%)
Cohort 2A: 12 mg LY3502970 Capsule QD0/50 (0%)0/50 (0%)7/50 (14%)
Cohort 2A: LY3502970 Tablet QD (Dose Level 10)0/50 (0%)0/50 (0%)16/50 (32%)
Cohort 2A:LY3502970 Tablet QD (Dose Level 11)0/50 (0%)0/50 (0%)11/50 (22%)
Cohort 2A: LY3502970 Tablet QD (Dose Level 12)0/50 (0%)0/50 (0%)8/50 (16%)
Cohort 2A: 24 mg LY3502970 Capsule QD0/50 (0%)0/50 (0%)13/50 (26%)
Cohort 2A: LY3502970 Tablet QD (Dose Level 13)0/49 (0%)1/49 (2%)10/49 (20.4%)
Cohort 2A: LY3502970 Tablet QD (Dose Level 14)0/49 (0%)0/49 (0%)13/49 (26.5%)
Cohort 2A: LY3502970 Tablet QD (Dose Level 15)0/50 (0%)0/50 (0%)10/50 (20%)
Cohort 2A: 36 mg LY3502970 Capsule QD0/45 (0%)0/45 (0%)9/45 (20%)
Cohort 2A: LY3502970 Tablet QD (Dose Level 16)0/45 (0%)0/45 (0%)9/45 (20%)
Cohort 2A:LY3502970 Tablet QD (Dose Level 17)0/45 (0%)0/45 (0%)9/45 (20%)
Cohort 2A: LY3502970 Tablet QD (Dose Level 18)0/45 (0%)0/45 (0%)9/45 (20%)
Cohort 1B: 1 mg LY3502970 Capsule QD0/215 (0%)0/215 (0%)92/215 (42.8%)
Cohort 1B: 0.8 mg LY3502970 Tablet QD0/213 (0%)0/213 (0%)49/213 (23%)
Cohort 1B: 3 mg LY3502970 Capsule QD0/210 (0%)0/210 (0%)96/210 (45.7%)
Cohort 1B: 2.5 mg LY3502970 Tablet QD0/210 (0%)0/210 (0%)57/210 (27.1%)
Cohort 1B: 6 mg LY3502970 Capsule QD0/203 (0%)1/203 (0.5%)80/203 (39.4%)
Cohort 1B:5.5 mg LY3502970 Tablet QD0/203 (0%)1/203 (0.5%)51/203 (25.1%)
Cohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing)0/213 (0%)0/213 (0%)111/213 (52.1%)
Cohort 2B:12 mg LY3502970 Capsule QD0/186 (0%)0/186 (0%)97/186 (52.2%)
Cohort 2B:9 mg LY3502970 Tablet QD0/186 (0%)0/186 (0%)61/186 (32.8%)
Cohort 2B:24 mg LY3502970 Capsule QD0/181 (0%)0/181 (0%)85/181 (47%)
Cohort 2B:14.5 mg LY3502970 Tablet QD0/180 (0%)0/180 (0%)56/180 (31.1%)
Cohort 2B: 36 mg LY3502970 Capsule QD0/176 (0%)1/176 (0.6%)66/176 (37.5%)
Cohort 2B: 17.2 mg LY3502970 Tablet QD0/176 (0%)0/176 (0%)35/176 (19.9%)
Most frequent serious events
Most frequent serious events
EventCohort 1A: 1 mg LY3502970 Capsule QDCohort 1A: LY3502970 Tablet QD (Dose Level 1)Cohort 1A: LY3502970 Tablet QD (Dose Level 2)Cohort 1A: LY3502970 Tablet QD (Dose Level 3)Cohort 1A: 3 mg LY3502970 Capsule QDCohort 1A: LY3502970 Tablet QD (Dose Level 4)Cohort 1A: LY3502970 Tablet QD (Dose Level 5)Cohort 1A: LY3502970 Tablet QD (Dose Level 6)Cohort 1A: 6 mg LY3502970 Capsule QDCohort 1A: LY3502970 Tablet QD (Dose Level 7)Cohort 1A: LY3502970 Tablet QD (Dose Level 8)Cohort 1A: LY3502970 Tablet QD (Dose Level 9)Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)Cohort 2A: 12 mg LY3502970 Capsule QDCohort 2A: LY3502970 Tablet QD (Dose Level 10)Cohort 2A:LY3502970 Tablet QD (Dose Level 11)Cohort 2A: LY3502970 Tablet QD (Dose Level 12)Cohort 2A: 24 mg LY3502970 Capsule QDCohort 2A: LY3502970 Tablet QD (Dose Level 13)Cohort 2A: LY3502970 Tablet QD (Dose Level 14)Cohort 2A: LY3502970 Tablet QD (Dose Level 15)Cohort 2A: 36 mg LY3502970 Capsule QDCohort 2A: LY3502970 Tablet QD (Dose Level 16)Cohort 2A:LY3502970 Tablet QD (Dose Level 17)Cohort 2A: LY3502970 Tablet QD (Dose Level 18)Cohort 1B: 1 mg LY3502970 Capsule QDCohort 1B: 0.8 mg LY3502970 Tablet QDCohort 1B: 3 mg LY3502970 Capsule QDCohort 1B: 2.5 mg LY3502970 Tablet QDCohort 1B: 6 mg LY3502970 Capsule QDCohort 1B:5.5 mg LY3502970 Tablet QDCohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing)Cohort 2B:12 mg LY3502970 Capsule QDCohort 2B:9 mg LY3502970 Tablet QDCohort 2B:24 mg LY3502970 Capsule QDCohort 2B:14.5 mg LY3502970 Tablet QDCohort 2B: 36 mg LY3502970 Capsule QDCohort 2B: 17.2 mg LY3502970 Tablet QD
HypersensitivityImmune system disorders0/520/520/520/520/470/510/480/510/460/460/470/460/520/500/500/500/500/501/490/490/500/450/450/450/450/2150/2130/2100/2100/2030/2030/2130/1860/1860/1810/1800/1760/176
Atrial fibrillationCardiac disorders0/520/520/520/520/470/510/480/510/460/460/470/460/520/500/500/500/500/500/490/490/500/450/450/450/450/2150/2130/2100/2100/2030/2030/2130/1860/1860/1810/1801/1760/176
Cholecystitis acuteHepatobiliary disorders0/520/520/520/520/470/510/480/510/460/460/470/460/520/500/500/500/500/500/490/490/500/450/450/450/450/2150/2130/2100/2101/2030/2030/2130/1860/1860/1810/1800/1760/176
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/520/520/520/520/470/510/480/510/460/460/470/460/520/500/500/500/500/500/490/490/500/450/450/450/450/2150/2130/2100/2100/2031/2030/2130/1860/1860/1810/1800/1760/176
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCohort 1A: 1 mg LY3502970 Capsule QDCohort 1A: LY3502970 Tablet QD (Dose Level 1)Cohort 1A: LY3502970 Tablet QD (Dose Level 2)Cohort 1A: LY3502970 Tablet QD (Dose Level 3)Cohort 1A: 3 mg LY3502970 Capsule QDCohort 1A: LY3502970 Tablet QD (Dose Level 4)Cohort 1A: LY3502970 Tablet QD (Dose Level 5)Cohort 1A: LY3502970 Tablet QD (Dose Level 6)Cohort 1A: 6 mg LY3502970 Capsule QDCohort 1A: LY3502970 Tablet QD (Dose Level 7)Cohort 1A: LY3502970 Tablet QD (Dose Level 8)Cohort 1A: LY3502970 Tablet QD (Dose Level 9)Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)Cohort 2A: 12 mg LY3502970 Capsule QDCohort 2A: LY3502970 Tablet QD (Dose Level 10)Cohort 2A:LY3502970 Tablet QD (Dose Level 11)Cohort 2A: LY3502970 Tablet QD (Dose Level 12)Cohort 2A: 24 mg LY3502970 Capsule QDCohort 2A: LY3502970 Tablet QD (Dose Level 13)Cohort 2A: LY3502970 Tablet QD (Dose Level 14)Cohort 2A: LY3502970 Tablet QD (Dose Level 15)Cohort 2A: 36 mg LY3502970 Capsule QDCohort 2A: LY3502970 Tablet QD (Dose Level 16)Cohort 2A:LY3502970 Tablet QD (Dose Level 17)Cohort 2A: LY3502970 Tablet QD (Dose Level 18)Cohort 1B: 1 mg LY3502970 Capsule QDCohort 1B: 0.8 mg LY3502970 Tablet QDCohort 1B: 3 mg LY3502970 Capsule QDCohort 1B: 2.5 mg LY3502970 Tablet QDCohort 1B: 6 mg LY3502970 Capsule QDCohort 1B:5.5 mg LY3502970 Tablet QDCohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing)Cohort 2B:12 mg LY3502970 Capsule QDCohort 2B:9 mg LY3502970 Tablet QDCohort 2B:24 mg LY3502970 Capsule QDCohort 2B:14.5 mg LY3502970 Tablet QDCohort 2B: 36 mg LY3502970 Capsule QDCohort 2B: 17.2 mg LY3502970 Tablet QD
ConstipationGastrointestinal disorders4/525/521/527/520/473/511/482/511/460/460/470/465/523/504/502/501/502/504/490/492/502/452/451/453/4558/21519/21320/21013/21015/20310/20339/21339/18617/18619/1816/1808/1765/176
NauseaGastrointestinal disorders1/520/521/521/522/474/514/482/510/463/462/475/467/523/503/501/504/502/502/492/494/501/450/456/452/4513/2157/21329/21013/21019/20317/20344/21332/18612/18631/18115/1809/1766/176
Decreased appetiteMetabolism and nutrition disorders1/520/520/520/521/470/510/480/510/460/460/470/461/520/501/500/500/500/500/490/491/501/450/450/450/458/2154/21315/2103/2103/2031/20343/2131/1865/1864/1815/1801/1762/176
HeadacheNervous system disorders1/521/521/520/521/472/513/482/514/462/462/473/465/522/503/502/503/505/501/493/492/503/452/453/451/4534/21519/21337/21017/21025/20317/20323/21336/18618/18618/18115/18028/1766/176
DiarrhoeaGastrointestinal disorders0/521/522/520/521/473/512/483/510/460/460/472/461/521/503/502/502/500/502/492/492/501/451/452/453/453/2152/2137/2103/2103/2033/20319/21319/1865/18623/18112/18011/1764/176
DizzinessNervous system disorders0/520/520/521/520/472/511/481/511/460/460/470/461/521/500/501/501/502/500/496/492/502/450/452/451/452/2152/2134/2103/2105/2031/2037/2139/1863/1868/1816/1806/1763/176
VomitingGastrointestinal disorders0/520/520/521/521/474/511/482/512/461/462/472/464/521/502/501/500/503/502/492/491/501/452/452/451/454/2154/21316/2107/21015/20310/20324/21322/18615/18617/1819/18019/17610/176
Heart rate increasedInvestigations0/520/520/520/520/470/510/480/510/460/460/470/460/520/500/501/501/501/500/491/491/500/454/451/450/450/2150/2133/2101/2101/2030/2035/2133/1862/1865/1812/1805/1764/176
DyspepsiaGastrointestinal disorders0/520/521/521/521/473/513/481/512/462/463/471/461/520/503/503/501/500/502/491/490/500/450/450/450/458/21510/21312/21012/21016/2039/20316/21314/1869/18613/1817/1808/1765/176
Abdominal distensionGastrointestinal disorders0/520/520/521/520/470/510/480/511/460/460/473/462/520/500/500/500/500/500/490/490/500/450/450/450/451/2152/2131/2102/2106/2031/20313/2136/1863/1869/1816/1802/1760/176

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(Years)Part A: LY3502970 Oral Administration - Cohort 1APart A: LY3502970 Oral Administration - Cohort 2APart B: LY3502970 Oral Administration - Cohort 1BPart B: LY3502970 Oral Administration - Cohort 2BTotal
Mean45.9 ± 10.7442.8 ± 10.2844.7 ± 11.1242.1 ± 10.5045.6 ± 10.83
Sex: Female, Male
Sex: Female, Male(Participants)Part A: LY3502970 Oral Administration - Cohort 1APart A: LY3502970 Oral Administration - Cohort 2APart B: LY3502970 Oral Administration - Cohort 1BPart B: LY3502970 Oral Administration - Cohort 2BTotal
Female22179382214
Male3035123131319
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: LY3502970 Oral Administration - Cohort 1APart A: LY3502970 Oral Administration - Cohort 2APart B: LY3502970 Oral Administration - Cohort 1BPart B: LY3502970 Oral Administration - Cohort 2BTotal
Hispanic or Latino11125366142
Not Hispanic or Latino4140163146390
Unknown or Not Reported00011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: LY3502970 Oral Administration - Cohort 1APart A: LY3502970 Oral Administration - Cohort 2APart B: LY3502970 Oral Administration - Cohort 1BPart B: LY3502970 Oral Administration - Cohort 2BTotal
American Indian or Alaska Native00527
Asian11259
Native Hawaiian or Other Pacific Islander00033
Black or African American22219981223
White2730106121284
More than one race20305
Unknown or Not Reported00112
Region of Enrollment
Region of Enrollment(Participants)Part A: LY3502970 Oral Administration - Cohort 1APart A: LY3502970 Oral Administration - Cohort 2APart B: LY3502970 Oral Administration - Cohort 1BPart B: LY3502970 Oral Administration - Cohort 2BTotal
United States5252216213533
08

Study locations

7 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Altasciences Company Inc.
    Overland Park, Kansas 66212, United States
  • QPS
    Springfield, Missouri 65802, United States
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
09

References and documents

Publications

  • Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes Obes Metab. 2026 Jul;28(7):5803-5809. doi: 10.1111/dom.70783. Epub 2026 Apr 17. PubMed 41994902 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jun 2025, 11 months.

Results were first posted in Jul 2026, 1 year 1 month after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Jun 24, 2024
Primary completionActual
Jun 2, 2025
CompletionActual
Jun 2, 2025
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06440980
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jun 24, 2024
Primary completion
Jun 2, 2025
Completion
Jun 2, 2025
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion